862402-79-7

Basic information

• Product Name: L-Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-O-propyl-, methyl ester
• CAS NO: 862402-79-7
• Molecular Formula: C18H27NO5
• Molecular Weight: 337.416
• Mol File: 862402-79-7.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: L-Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-O-propyl-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: L-Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-O-propyl-, methyl ester(862402-79-7)
• EPA Substance Registry System: L-Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-O-propyl-, methyl ester(862402-79-7)

Safety Data

• Hazardous Substances Data: 862402-79-7(Hazardous Substances Data)

Upstream product

• 1912-31-8 propyl methanesulfonate 
• 4326-36-7 (S)-N-(tert-butoxycarbonyl)tyrosine methyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 60-18-4 L-tyrosine 
• 147363-23-3 methyl (2S)-2-{[(tert-butoxy)carbonyl]amino}-3-[4-(prop-2-en-1-yloxy)phenyl]-propanoate 
• 107-08-4 1-iodo-propane 
• 3417-91-2 L-tyrosine methyl ester HCl 

Downstream Products

• 76757-93-2 (S)-2-((tert-butoxycarbonyl)amino)-3-(4-propoxyphenyl)propanoic acid 

Relevant articles and documents

Improved binding affinities of pyrrolidine derivatives as Mcl-1 inhibitors by modifying amino acid side chains

As an important member of anti-apoptotic Bcl-2 protein, myeloid cell leukemia sequence 1 (Mcl-1) protein is an attractive target for cancer therapy. In this study, a new series of pyrrolidine derivatives as Mcl-1 inhibitors were developed by mainly modifying the amino acid side chain of compound 1. Among them, compound 18 (Ki= 0.077 μM) exhibited better potent inhibitory activities towards Mcl-1 protein compared to positive control Gossypol (Ki= 0.18 μM). In addition, compound 40 possessed good antiproliferative activities against PC-3 cells (Ki= 8.45 μM), which was the same as positive control Gossypol (Ki= 7.54 μM).

HYDROXAMIC ACID DERIVATIVE AND AGE GENERATION INHIBITOR CONTAINING THE DERIVATIVE

To provide a novel compound which inhibits the generation of AGE and an AGE generation inhibitor containing the compound. A compound represented by the following formula or a pharmaceutically acceptable salt thereof, a medicinal composition containing the compound or such a salt thereof, and an additive composition containing the compound.